Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Google Disrupts Major Residential Proxy Network IPIDEA 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
MENLO PARK, Calif., May 22, 2017 -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, announced today that Amber Salzman, Ph.D., president and chief executive officer, will present at the Jefferies Global Healthcare Conference.
| Event: | Jefferies Global Healthcare Conference |
| Date: | June 7, 2017 |
| Time: | 1:30 – 2:00 p.m. ET |
| Location: | New York, NY |
A live and replay video webcast of the presentation will be available from Adverum’s website at http://investors.adverum.com.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that can offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat wet age-related macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Contacts for Adverum: Leone Patterson Chief Financial Officer Adverum Biotechnologies, Inc. 650-665-7222 [email protected] Tricia Truehart Vice President The Trout Group LLC 646-378-2953 [email protected]
